Wiener Medizinische Wochenschrift

, Volume 157, Issue 23–24, pp 589–592 | Cite as

Treatment and prevention of osteoporosis

Themenschwerpunkt

Summary

Osteoporosis is recognized as a major health threat. The number of patients will certainly grow with the aging of the population. While preventive strategies, such as calcium, vitamin D, exercise and reduced risk factors may diminish the impact of menopause and age-regulated bone loss, many patients will become candidates for pharmacologic therapy. A variety of options are available, including HRT, bisphosphonates, SERMs, calcitonin, strontium ranelate, teriparatid. New forms of treatment are appearing on the horizon, such as monoclonal antibodies, nitrates, beta-blockers and Cathepsin K inhibitors.

Keywords

Osteoporosis Basic treatment Antiresorptives Anabolics Mixed effects Future trends 

Therapie und Prevention der Osteoporose

Zusammenfassung

Die Osteoporose wurde in den letzten Jahren als wesentliches Gesundheitsproblem erkannt; mit dem zunehmenden Alter der Bevölkerung wird die Zahl an Osteoporosepatienten deutlich zunehmen. Obwohl Präventionsstrategien wie Kalzium, Vitamin D, Bewegung und die Verminderung von Risikofaktoren die Auswirkungen des postmenopausalen und altersabhängigen Knochenverlustes vermindern können, werden viele Patienten Kandidaten für eine pharmakologische Therapie werden. Zur pharmakologischen Behandlung der Osteoporose sind eine Vielzahl von Optionen wie die Hormonersatztherapie, Bisphosphonate, SERMs, Kalzitonin, Strontiumranelat und Teriparatid verfügbar. Monoklonale Antikörper, Nitrate, Beta-Blocker und Cathepsin K-inhibitoren könnten neue zukünftige Behandlungsstrategien darstellen.

Schlüsselwörter

Osteoporose Basistherapie Antiresorptiva Anabolika Kombinationseffekte Zukunftsaspekte 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lee SH, Dargent-Molina P, Bréart G; EPIDOS Group. Epidemiologie de l'Osteoporose Study (2002) Risk factors for fractures of the proximal humerus: results from the EPIDOS prospective study. J Bone Miner Res 17: 817–825CrossRefPubMedGoogle Scholar
  2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee The Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701–1712CrossRefPubMedGoogle Scholar
  3. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125–137CrossRefGoogle Scholar
  4. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315–1322CrossRefPubMedGoogle Scholar
  5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822CrossRefPubMedGoogle Scholar
  6. Bilezikian JP (2006) Osteonecrosis of the jaw – do bisphosphonates pose a risk? N Engl J Med 355: 2278–2281CrossRefPubMedGoogle Scholar
  7. Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 18(Suppl 1): S11–S15CrossRefPubMedGoogle Scholar
  8. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Endocrine Unit and OsteocentreCentral Military HospitalPragueCzech Republic

Personalised recommendations